|
India Guidance Standardizes Adverse Event Reporting
India’s Drugs Controller General has released new industry guidance to combat formatting inconsistences and speed up processing for reports of serious adverse events (SAEs) in clinical trials.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives